A5512

Sigma-Aldrich

Aristolochic acid I

powder

Synonym(s):
TR 1736
Empirical Formula (Hill Notation):
C17H11NO7
CAS Number:
Molecular Weight:
341.27
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.77
Pricing and availability is not currently available.

assay

≥90% (HPLC)

form

powder

color

yellow

mp

269-270 °C

solubility

DMSO: soluble
ethanol: soluble

storage temp.

2-8°C

SMILES string

COc1cccc2c1cc([N+]([O-])=O)c3c(cc4OCOc4c23)C(O)=O

InChI

1S/C17H11NO7/c1-23-12-4-2-3-8-9(12)5-11(18(21)22)14-10(17(19)20)6-13-16(15(8)14)25-7-24-13/h2-6H,7H2,1H3,(H,19,20)

InChI key

BBFQZRXNYIEMAW-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Aristolochic acid I is a potent phospholipase A2 inhibitor. Aristolochic acid I induces tumor formation in rat kidneys and apoptosis in human renal proximal tubular epithelial cells.

Packaging

25 mg in poly bottle
100 mg in glass bottle

Biochem/physiol Actions

Potent phospholipase A2 inhibitor, including calcium ionophore-induced phospholipase A2 activity in neutrophils. Kidney tumor initiator in experimental animal model.

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Statements

Precautionary Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

UN 1544PSN1 6.1 / PGIII

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Shenyang Li et al.
American journal of physiology. Renal physiology, 305(5), F618-F627 (2013-06-28)
We examined the effects of increased expression of proximal tubule peroxisome proliferator-activated receptor (PPAR)α in a mouse model of renal fibrosis. After 5 days of unilateral ureteral obstruction (UUO), PPARα expression was significantly reduced in kidney tissue of wild-type mice...
Zhenzhou Jiang et al.
Toxicology and applied pharmacology, 266(2), 198-203 (2012-07-24)
This report describes an investigation of the pathological mechanism of acute renal failure caused by toxic tubular necrosis after treatment with aristolochic acid I (AAI) in Sprague-Dawley (SD) rats. The rats were gavaged with AAI at 0, 5, 20, or...
Yongheng Bai et al.
Molecular medicine reports, 16(1), 737-745 (2017-06-01)
Sedum sarmentosum Bunge (SSBE) is a perennial plant widely distributed in Asian countries, and its extract is traditionally used for the treatment of certain inflammatory diseases. Our previous studies demonstrated that SSBE has marked renal anti‑fibrotic effects. However, the underlying molecular...
Youjia Zeng et al.
PloS one, 7(1), e30312-e30312 (2012-01-26)
Autophagy is a lysosomal degradation pathway that is essential for cell survival and tissue homeostasis. However, limited information is available about autophagy in aristolochic acid (AA) nephropathy. In this study, we investigated the role of autophagy and related signaling pathway...
Jie Wei et al.
Journal of chromatography. A, 1246, 129-136 (2012-04-10)
A novel silica-based reversed-phase/strong anion-exchange mixed-mode stationary phase named C18SAX was synthesized based on the polar-copolymerized approach. C18SAX stationary phase showed excellent compatibility with 100% aqueous mobile phase and comparable performance with commercial SunFire™ C18 column in terms of column...
Articles
Cancer research has revealed that the classical model of carcinogenesis, a three step process consisting of initiation, promotion, and progression, is not complete.
Read More
Related Content
Discover Bioactive Small Molecules for Lipid Signaling Research
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.